PE20160116A1 - Composiciones antimicrobianas - Google Patents

Composiciones antimicrobianas

Info

Publication number
PE20160116A1
PE20160116A1 PE2015002523A PE2015002523A PE20160116A1 PE 20160116 A1 PE20160116 A1 PE 20160116A1 PE 2015002523 A PE2015002523 A PE 2015002523A PE 2015002523 A PE2015002523 A PE 2015002523A PE 20160116 A1 PE20160116 A1 PE 20160116A1
Authority
PE
Peru
Prior art keywords
compositions
carboxylic acid
acid derivative
glucitol
azetidinyl
Prior art date
Application number
PE2015002523A
Other languages
English (en)
Inventor
Danping Li
Eric S Burak
David S Dresback
Danielle Beurer Lord
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42170697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160116(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of PE20160116A1 publication Critical patent/PE20160116A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)

Abstract

La presente invencion se refiere a composiciones antimicrobianas y mas especificamente composiciones de derivados del acido carboxilico. estas composiciones tienen solubilidad, estabilidad y tolerabilidad mejorada. Estas composiciones son utiles para la administracion intravenosa para tratar, prevenir, o reducir el riesgo de infeccion. Dicho derivado del acido carboxilico de quinalona es un D-glucitol, 1-deoxi-1-(metilamino)-, 1-(6-amino-3,5-difluoro-2-piridinil)-8-cloro-6-fluoro-1,4-dihidro-7-(3-hidroxi-1-azetidinil)-4-oxo-3-quinolinacarboxilato (sal), O dicho derivado del acido carboxilico de quinolona es D-glucitol cristalino, 1-deoxi-1-(metilamino)-, 1-( 6-amino-3,5-difluoro-2-piridinil)-8-cloro-6-fluoro-1,4-dihidro-7 -(3-hidroxi-1-azetidinil)-4-oxo-3 -quinolinacarboxilato trihidrato (sal)
PE2015002523A 2008-11-15 2009-11-12 Composiciones antimicrobianas PE20160116A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19925308P 2008-11-15 2008-11-15

Publications (1)

Publication Number Publication Date
PE20160116A1 true PE20160116A1 (es) 2016-03-09

Family

ID=42170697

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001038A PE20120029A1 (es) 2008-11-15 2009-11-12 Composiciones antimicrobianas
PE2015002523A PE20160116A1 (es) 2008-11-15 2009-11-12 Composiciones antimicrobianas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2011001038A PE20120029A1 (es) 2008-11-15 2009-11-12 Composiciones antimicrobianas

Country Status (24)

Country Link
US (4) US20120065186A1 (es)
EP (1) EP2373166A4 (es)
JP (3) JP6063123B2 (es)
KR (1) KR101767689B1 (es)
CN (3) CN102215690B (es)
AU (1) AU2009314072C1 (es)
BR (2) BR122020021551B1 (es)
CA (1) CA2743419C (es)
CO (1) CO6382082A2 (es)
CR (1) CR20110320A (es)
EA (1) EA025637B1 (es)
EC (1) ECSP11011119A (es)
HK (1) HK1213821A1 (es)
IL (1) IL212781A (es)
MA (1) MA32931B1 (es)
MX (1) MX2011005117A (es)
MY (3) MY188453A (es)
NI (1) NI201100097A (es)
NZ (1) NZ593345A (es)
PE (2) PE20120029A1 (es)
SV (1) SV2011003907A (es)
UA (1) UA102709C2 (es)
WO (1) WO2010056872A2 (es)
ZA (1) ZA201104108B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2373166A4 (en) * 2008-11-15 2014-11-05 Rib X Pharmaceuticals Inc ANTIMICROBIAL COMPOSITIONS
DK2785352T3 (da) * 2011-11-29 2020-05-25 Jurox Pty Ltd Stabile injicerbare farmaceutiske sammensætninger omfattende 2-hydroxypropyl-beta-cyclodextrin og alfaxalon
JP6395200B2 (ja) * 2012-10-22 2018-09-26 ジェクス株式会社 ケイ素含有化合物水溶液及び該水溶液を含む抗菌・抗ウィルス剤
US20160046603A1 (en) * 2013-03-08 2016-02-18 Melinta Therapeutics, Inc. Crystalline Forms of D-Glucitol, 1-Deoxy-1-(Methylamino)-, 1-(6-Amino-3,5-Difluoropyridine-2-Yl)-8-Chloro-6-Fluoro-1,4-Dihydro-7-(3-Hydroxyazetidin-1-Yl)-4-Oxo-3-Quinolinecarboxylate
AU2014239965A1 (en) * 2013-03-15 2015-09-24 Melinta Subsidiary Corp. Methods of treating infections in overweight and obese patients using antibiotics
SI3122358T1 (sl) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka
TWI732337B (zh) * 2014-06-20 2021-07-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
TW201605447A (zh) * 2014-06-20 2016-02-16 美林塔治療學有限公司 處理感染的方法
CN105693695A (zh) * 2014-11-24 2016-06-22 重庆医药工业研究院有限责任公司 一种德拉沙星葡甲胺盐的晶型及其制备方法
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
CA3016809C (en) 2016-03-14 2024-03-12 Santen Pharmaceutical Co., Ltd. Antiseptic agent comprising meglumine or salt thereof
CN107789323B (zh) * 2016-08-31 2021-05-07 鲁南制药集团股份有限公司 一种注射用德拉沙星葡甲胺冻干制剂及其制备方法
CN107789324B (zh) * 2016-08-31 2021-05-25 鲁南制药集团股份有限公司 一种注射用德拉沙星葡甲胺及其制备方法
MA47516A (fr) * 2017-02-15 2021-03-31 Taiho Pharmaceutical Co Ltd Composition pharmaceutique

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US436A (en) 1837-10-23 Brick mold used in brick-pressing machines
US5998A (en) 1849-01-02 Improvement in combined plows
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5084276A (en) 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
RU2177945C1 (ru) 1995-09-22 2002-01-10 Вакунага Фармасьютикал КО., Лтд. Производное пиридонкарбоновой кислоты или его соль
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6685958B2 (en) * 2001-04-25 2004-02-03 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
JP2005097116A (ja) 1999-11-11 2005-04-14 Wakunaga Pharmaceut Co Ltd キノリンカルボン酸誘導体アルカリ金属塩及びこれを用いたキノリンカルボン酸誘導体の精製法
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc PREPARATION CONTAINING PROPOFOL AND SULFOALKYL ETHER CYCLODEXTRIN
US20070049552A1 (en) * 2003-04-14 2007-03-01 Babu Manoj M Fluoroquinolone formulations and methods of making and using the same
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
EP2305666B1 (en) 2004-07-30 2014-06-25 AbbVie Inc. Preparation of pyridonecarboxylic acid antibacterials
LT3056492T (lt) 2004-10-08 2022-01-25 Abbvie Inc. Meglumino druska ir atitinkamos vaisto (delafloksacino) kristalinės formos
CA2603783C (en) 2005-04-11 2014-11-18 Abbott Laboratories Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
US20070238720A1 (en) * 2005-05-10 2007-10-11 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
WO2006134877A1 (ja) * 2005-06-13 2006-12-21 Takeda Pharmaceutical Company Limited 注射剤
US20070197469A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
EP2373166A4 (en) * 2008-11-15 2014-11-05 Rib X Pharmaceuticals Inc ANTIMICROBIAL COMPOSITIONS

Also Published As

Publication number Publication date
BRPI0921705B8 (pt) 2021-05-25
SV2011003907A (es) 2011-12-06
JP6407221B2 (ja) 2018-10-17
BR122020021551B1 (pt) 2021-09-21
IL212781A0 (en) 2011-07-31
CN103705942B (zh) 2016-08-24
AU2009314072C1 (en) 2016-11-10
IL212781A (en) 2016-12-29
JP2017031164A (ja) 2017-02-09
BRPI0921705B1 (pt) 2021-01-19
MX2011005117A (es) 2011-10-21
US20220265636A1 (en) 2022-08-25
AU2009314072B2 (en) 2016-05-19
CN104958296A (zh) 2015-10-07
KR20120008020A (ko) 2012-01-25
CN102215690A (zh) 2011-10-12
NZ593345A (en) 2013-04-26
EP2373166A4 (en) 2014-11-05
CA2743419C (en) 2017-02-14
JP2015091856A (ja) 2015-05-14
CR20110320A (es) 2011-10-18
PE20120029A1 (es) 2012-02-13
EA201170689A1 (ru) 2013-10-30
CN104958296B (zh) 2017-12-01
CN103705942A (zh) 2014-04-09
CO6382082A2 (es) 2012-02-15
JP2012508757A (ja) 2012-04-12
HK1213821A1 (zh) 2016-07-15
ZA201104108B (en) 2012-09-26
CN102215690B (zh) 2015-07-01
AU2009314072A1 (en) 2011-06-30
MA32931B1 (fr) 2012-01-02
KR101767689B1 (ko) 2017-08-11
CA2743419A1 (en) 2010-05-20
US20160235736A1 (en) 2016-08-18
ECSP11011119A (es) 2011-11-30
WO2010056872A2 (en) 2010-05-20
US20120065186A1 (en) 2012-03-15
NI201100097A (es) 2011-09-08
EA025637B1 (ru) 2017-01-30
JP6063123B2 (ja) 2017-01-18
UA102709C2 (uk) 2013-08-12
BRPI0921705A2 (pt) 2015-08-25
MY194407A (en) 2022-11-30
US20200022971A1 (en) 2020-01-23
WO2010056872A3 (en) 2010-07-29
MY161597A (en) 2017-04-28
MY188453A (en) 2021-12-09
EP2373166A2 (en) 2011-10-12

Similar Documents

Publication Publication Date Title
PE20160116A1 (es) Composiciones antimicrobianas
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
MX348653B (es) Derivados ester de acido boronico ciclico y sus usos terapeuticos.
IN2012DN01453A (es)
TN2016000090A1 (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors.
EA201390198A1 (ru) Гетероциклическое соединение
UY35146A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
ECSP12012171A (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos
GT201100336A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
NZ596628A (en) Ketolide compounds having antimicrobial activity
PE20150774A1 (es) Aminoquinolinas como inhibidores de cinasa
MX341220B (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas.
CO6612202A2 (es) Inhibidores heterparílicos bicíclicos de pde4
ECSP10010428A (es) Derivados de indazol
WO2011006935A3 (en) Tetrazole derivatives
PE20120500A1 (es) Piperidinas sustituidas con heteroilamino y aroilamino como inhibidores de glyt-1
HK1149263A1 (en) Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
MX2015010434A (es) Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo.
CL2020003153A1 (es) Composiciones antimicrobianas con agentes efervescentes (divisional de solicitud n° 03273-2016)
EA201170368A1 (ru) Противомикробная композиция
GT200900295A (es) Composición farmacéutica que comprende la combinación del agente antimicrobiano ciprofloxacino y el agente antioxidante ácido ascórbico para el tratamiento de infecciones urinarias.
EA201390764A1 (ru) Фармацевтические композиции

Legal Events

Date Code Title Description
FC Refusal